3.19

4.63% -0.155

After Hours: 3.19

Poseida Therapeutics Inc (PSTX)

Overview News Price History Option Chain Financials Discussions Forecast

Poseida Therapeutics Inc stock is currently priced at $3.19, with a 24-hour trading volume of 517.57K. It has seen a -4.63% decreased in the last 24 hours and a +56.37% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.40 pivot point. If it approaches the $3.15 support level, significant changes may occur.

Previous Close:

$3.345

Open:

$3.34

24h Volume:

517.57K

Market Cap:

$309.29M

Revenue:

$64.70M

Net Income/Loss:

$-123.43M

P/E Ratio:

-13.29

EPS:

-0.24

Net Cash Flow:

$-95.23M

1W Performance:

+20.60%

1M Performance:

+56.37%

6M Performance:

+40.53%

1Y Performance:

+18.15%

1D Range:

$3.12

$3.3821

52W Range:

$1.54

$4.27

Poseida Therapeutics Inc Stock (PSTX) Company Profile

Name

Poseida Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

858-779-3100

Address

4242 Campus Point Court, Suite 700, San Diego

Employee

149

Twitter

Next Earnings Date

2024-06-14

Latest SEC Filings

PSTX's Discussions on Twitter

Poseida Therapeutics Inc Stock (PSTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-04-23	Initiated	H.C. Wainwright	Buy
Jan-07-22	Initiated	Cantor Fitzgerald	Overweight
May-18-21	Initiated	BTIG Research	Buy
Aug-04-20	Initiated	BofA Securities	Buy
Aug-04-20	Initiated	Piper Sandler	Overweight
Aug-04-20	Initiated	William Blair	Outperform

View All

Poseida Therapeutics Inc Stock (PSTX) Latest News

Biotech Soars on Research Collaboration And License Agreement Release - The Globe and Mail

The Globe and Mail

William Blair Weighs in on Poseida Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:PSTX) - Defense World

Defense World

Q2 2024 EPS Estimates for Poseida Therapeutics, Inc. (NASDAQ:PSTX) Cut by Analyst - MarketBeat

MarketBeat

Poseida Therapeutics Inc (PSTX) Stock: Uncovering 52-Week Market Trends - The InvestChronicle

The InvestChronicle

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 - PR Newswire

PR Newswire

Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research

Poseida Therapeutics Inc Stock (PSTX) Financials Data

Poseida Therapeutics Inc (PSTX) Revenue 2024

PSTX reported a revenue (TTM) of $64.70 million for the quarter ending December 31, 2023, a -50.42% decline year-over-year.

Poseida Therapeutics Inc (PSTX) Net Income 2024

PSTX net income (TTM) was -$123.43 million for the quarter ending December 31, 2023, a -92.85% decrease year-over-year.

Poseida Therapeutics Inc (PSTX) Cash Flow 2024

PSTX recorded a free cash flow (TTM) of -$95.23 million for the quarter ending December 31, 2023, a -210.25% decrease year-over-year.

Poseida Therapeutics Inc (PSTX) Earnings per Share 2024

PSTX earnings per share (TTM) was -$1.38 for the quarter ending December 31, 2023, a -26.61% decline year-over-year.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.